Literature DB >> 32135512

Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy.

William R Kennedy1, Christopher Tricarico1, Prashant Gabani1, Ashley A Weiner2, Michael B Altman1, Laura L Ochoa1, Maria A Thomas1, Julie A Margenthaler3, Souzan Sanati4, Lindsay L Peterson5, Cynthia X Ma5, Foluso O Ademuyiwa5, Imran Zoberi1.   

Abstract

BACKGROUND: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) predicts decreased distant metastasis. However, most patients do not experience pCR, and other risk factors for distant metastasis after NAC are poorly characterized. This study investigated factors predictive of distant metastasis in TNBC without pCR after NAC.
METHODS: Women with TNBC treated with NAC, surgery, and radiation therapy in 2000 through 2013 were reviewed. Freedom from distant metastasis (FFDM) was compared between patients with and without pCR using the Kaplan-Meier method. In patients without pCR, univariate and multivariable Cox analyses were used to determine factors predictive of distant metastasis.
RESULTS: We identified 153 patients with median follow-up of 4.0 years (range, 0.5-14.0 years). After NAC, 108 had residual disease (pCR, 29%). Five-year FFDM was 98% and 55% in patients with and without pCR, respectively (P<.001). Factors independently predicting FFDM in patients without pCR were pathologic nodal positivity (hazard ratio, 3.08; 95% CI, 1.54-6.14; P=.001) and lymphovascular space invasion (hazard ratio, 1.91; 95% CI, 1.07-3.43; P=.030). Patients with a greater number of factors had worse FFDM; 5-year FFDM was 76.5% for patients with no factors (n=38) versus 54.9% and 27.5% for patients with 1 (n=44) and 2 factors (n=26), respectively (P<.001).
CONCLUSIONS: Lack of pCR after NAC resulted in worse overall survival and FFDM, despite trimodality therapy. In patients with residual disease after NAC, pathologic lymph node positivity and lymphovascular space invasion predicted worse FFDM.

Entities:  

Mesh:

Year:  2020        PMID: 32135512     DOI: 10.6004/jnccn.2019.7366

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  3 in total

1.  Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.

Authors:  James D Hampton; Erica J Peterson; Nicholas P Farrell; Jennifer E Koblinski; Samantha J Katner; Tia H Turner; Mohammad A Alzubi; J Chuck Harrell; Mikhail G Dozmorov; Joseph B McGee Turner; Pam J Gigliotti; Vita Kraskauskiene; Mayuri Shende; Michael O Idowu; Madhavi Puchalapalli; Bin Hu; Larisa Litovchick; Eriko Katsuta; Kazuaki Takabe
Journal:  Mol Cancer Ther       Date:  2021-11-23       Impact factor: 6.009

2.  Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.

Authors:  Haeyoung Kim; Yeon Jeong Kim; Donghyun Park; Woong-Yang Park; Doo Ho Choi; Won Park; Won Kyung Cho; Nalee Kim
Journal:  Breast Cancer Res Treat       Date:  2021-06-21       Impact factor: 4.872

Review 3.  Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.

Authors:  Amy H Tang; Richard A Hoefer; Mary L Guye; Harry D Bear
Journal:  Cancer Drug Resist       Date:  2022-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.